The University of Connecticut and emerging immunotherapy company CaroGen have begun a collaboration to develop a vaccine for treatment of patients with colon cancer. CaroGen’s proprietary technology platform will be applied to a specific target studied by UConn Health researchers .​.. more

IsoPlexis has won a competitive Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health to develop a system to analyze trafficking leukocytes’ highly multiplexed proteomic responses in patients with Alzheimer’s disease .​.. more